Consultant Cardiologist, Department of Cardiology, SHS Memorial Hospital and Maternity Centre, Jammu, Jammu and Kashmir, India, Corresponding Author.
Senior Consultant Cardiologist and Director, Adjunct Associate Professor, Department of Interventional Cardiology, Apollo Hospital, Apollo Hospitals Educational & Research Foundation (AHERF), Bhubaneswar, Odisha, India.
J Assoc Physicians India. 2024 Sep;72(9S):16-18. doi: 10.59556/japi.72.0671.
Loop diuretics are regarded as essential for the treatment of edematous conditions in heart failure, cirrhosis, and renal disease. The principal mechanism of action involves inhibiting the reabsorption of ions (Na+, 2Cl-, and K+) from the ascending loop of Henle. The pharmacokinetic (PK) and pharmacodynamic (PD) features of the commonly used diuretics (torsemide, furosemide, and bumetanide) influence the selection of diuretics in various disease states and dosing regimens. However, torsemide demonstrates superior PK and PD qualities, making it the preferred choice. Genetic polymorphisms must be explored to better understand the diversity of PK and PD parameters of loop diuretics between individuals.
袢利尿剂被认为是心力衰竭、肝硬化和肾病水肿治疗的基本药物。其主要作用机制包括抑制从亨利氏袢升支重吸收离子（Na+、2Cl-和 K+）。常用利尿剂（托塞米、呋塞米和布美他尼）的药代动力学（PK）和药效动力学（PD）特征影响各种疾病状态和剂量方案中利尿剂的选择。然而，托塞米具有更优的 PK 和 PD 特性，是首选。必须探索遗传多态性，以更好地理解个体间袢利尿剂 PK 和 PD 参数的多样性。
